NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

10656	Companies
226864	Keywords
155330	Articles
120135	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 09/26/2024 at 12:30, 1 year 9 months ago

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
NanoViricides, Inc. obtains right of first refusal for antiviral drug developments from TheraCour Pharma, expands drug portfolio with new MOU and revolutionary nanoviricide technology, including NV-387 for multiple viral infections

NV-387 Antiviral Drugs NanoViricides Inc. TheraCour Pharma Nanoviricide Technology
BRIEF

published on 08/26/2024 at 13:35, 1 year 10 months ago

NanoViricides Investigates NV-387 for MPOX Treatment Under WHO's MEURI Protocol

NanoViricides NV-387 Mpox WHO MEURI Protocol
BRIEF

published on 08/26/2024 at 13:35, 1 year 10 months ago

NanoViricides étudie le NV-387 pour le traitement du MPOX dans le cadre du protocole MEURI de l'OMS

NanoViricides NV-387 Mpox Protocole MEURI OMS
PRESS RELEASE

published on 08/26/2024 at 13:30, 1 year 10 months ago

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
NanoViricides, Inc. reports investigating NV-387 for MPOX treatment under WHO MEURI protocol amidst 2024 outbreak. NV-387 shows promise in animal studies for broad-spectrum antiviral use

NanoViricides NV-387 Broad-spectrum Antiviral MPOX Treatment WHO MEURI Protocol
BRIEF

published on 08/19/2024 at 12:35, 1 year 10 months ago

NanoViricides Advances Towards Phase II Trial of NV-387

NanoViricides NV-387 Antiviral Therapy Phase II Trial RSV, COVID, Influenza
BRIEF

published on 08/19/2024 at 12:35, 1 year 10 months ago

NanoViricides avance vers la phase II de l'essai du NV-387

NanoViricides NV-387 Essai De Phase II Thérapie Antivirale VRS, COVID, Grippe
PRESS RELEASE

published on 08/19/2024 at 12:30, 1 year 10 months ago

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
NanoViricides, Inc. provides update on Phase II clinical trial plans for broad-spectrum antiviral drug candidate NV-387 against RSV, COVID, and Influenza. Potential $12 Billion market. Novel trial design expected

NanoViricides NV-387 Clinical Trial Antiviral Phase II
BRIEF

published on 08/08/2024 at 12:35, 1 year 10 months ago

NanoViricides Updates Clinical Program and Strategy

NV-387 Clinical Trials RSV Treatment Antiviral Nanomedicines Broad-spectrum Antiviral
BRIEF

published on 08/08/2024 at 12:35, 1 year 10 months ago

NanoViricides met à jour son programme clinique et sa stratégie

NV-387 Essais Cliniques Antiviral À Large Spectre Nanomédicaments Antiviraux Traitement Du VRS
PRESS RELEASE

published on 08/08/2024 at 12:30, 1 year 10 months ago

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics
NanoViricides provides update on clinical program & strategy for novel antiviral drug NV-387, targeting Influenza, COVID, RSV & more. Broad-spectrum potential discussed

NanoViricides NV-387 Clinical Program Antiviral Drug Broad-spectrum

Accesswire

Published on 06/30/2026 at 02:00, 25 minutes ago

MedMira Reports Third Quarter Results FY2026
Published on 06/30/2026 at 00:05, 2 hours 20 minutes ago

American Critical Minerals Announces Completion of Warrant Exercise Incentive Program
Published on 06/29/2026 at 23:46, 2 hours 39 minutes ago

1933 Industries Reports Third Quarter 2026 Financial Results
Published on 06/29/2026 at 22:01, 4 hours 24 minutes ago

AIP Realty Trust Announces Voting Results of Annual General and Special Meeting of Unitholders
Published on 06/29/2026 at 15:00, 11 hours 25 minutes ago

Infield Minerals Significantly Expands Land Holdings and Builds Regional Presence at the Detroit Gold Project in Utah

View all ACCESSWIRE

EQS Group

Published on 06/29/2026 at 22:47, 3 hours 38 minutes ago

Correction d’un communiqué du 29.06.2026 22:05 CET/CEST - ABIVAX: Résultats positifs de la partie 2 de maintenance ABTECT démontrant bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les ...
Published on 06/29/2026 at 22:05, 4 hours 20 minutes ago

ABIVAX: Résultats positifs de la partie 2 de l’essai de maintenance ABTECT démontrant bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les données de sécurité
Published on 06/29/2026 at 22:05, 4 hours 20 minutes ago

Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory UC Patients and Strengthening the Phase 3 Maintenance Safety Database
Published on 06/29/2026 at 20:30, 5 hours 55 minutes ago

Shelly Group SE: Annual General Meeting approves dividend of EUR 0.13 per share – shareholders approve all agenda items
Published on 06/29/2026 at 20:00, 6 hours 25 minutes ago

IGEL Appoints James Millington as Field CTO for Healthcare in EMEA

Les Echos

Published on 06/29/2026 at 18:30, 7 hours 55 minutes ago

Accor and H World Group expand long-term partnership across direct booking and loyalty platforms
Published on 06/29/2026 at 18:30, 7 hours 55 minutes ago

Accor et H World Group : extension du partenariat de long terme aux plateformes de réservation directe et de fidélité
Published on 06/29/2026 at 17:45, 8 hours 40 minutes ago

Successful issue of a € 1.5 billion bond
Published on 06/29/2026 at 17:45, 8 hours 40 minutes ago

Succès de l’émission obligataire de 1,5 milliard d’euros
Published on 06/29/2026 at 17:45, 8 hours 40 minutes ago

Déclaration hebdomadaire de rachat d'actions

View all LES ECHOS COMFI WIRE